文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌消化内镜

胃异型增生内镜切除后幽门螺杆菌治疗与胃癌风险:一项全国性队列研究

Helicobacter pylori Treatment and Gastric Cancer Risk After Endoscopic Resection of Dysplasia: A Nationwide Cohort Study.
PubMed 文献 · Gastroenterology · 2023-10-18

该研究基于韩国全国保险数据,纳入2010年至2020年间因胃异型增生接受内镜切除的患者,分析幽门螺杆菌治疗与新发胃癌及异时性胃肿瘤的关联。中位随访5.6年期间,接受幽门螺杆菌治疗与较低的胃癌风险相关(aHR 0.88,95%CI 0.80-0.96),并与异时性胃肿瘤风险降低相关(aHR 0.76,95%CI 0.70-0.82)。

要点

  • 胃异型增生内镜切除后接受幽门螺杆菌治疗与胃癌风险降低相关(aHR 0.88)
  • 幽门螺杆菌治疗与异时性胃肿瘤风险降低相关(aHR 0.76)
  • ≥3年及≥5年迟发型胃癌风险亦见降低(aHR 分别为0.84、0.80)

核心结论

  • 在这项全国性队列中,胃异型增生内镜切除后接受幽门螺杆菌治疗与胃癌及异时性胃肿瘤发生风险降低相关。

研究设计与样本

  • 基于韩国全国保险数据的全国性队列研究,纳入2010年至2020年间因胃异型增生接受内镜切除的患者69,722例,其中49.5%接受幽门螺杆菌治疗。
  • 以幽门螺杆菌治疗状态为时间依赖协变量,采用多变量Cox回归模型评估胃癌及异时性胃肿瘤风险。
  • 索引内镜切除1年后发生的新发胃癌与异时性胃肿瘤(包括癌和异型增生)为观察结局,新诊断胃癌≥3年及≥5年定义为迟发型胃癌。

主要发现

  • 中位随访5.6年期间,2406例发生胃癌,3342例发生异时性胃肿瘤。
  • 接受幽门螺杆菌治疗与较低的胃癌风险密切相关(aHR 0.88;95%CI 0.80-0.96)。
  • 幽门螺杆菌治疗显著降低异时性胃肿瘤发生(aHR 0.76;95%CI 0.70-0.82)。
  • 幽门螺杆菌治疗对≥3年迟发型胃癌(aHR 0.84;95%CI 0.75-0.94)和≥5年迟发型胃癌(aHR 0.80;95%CI 0.68-0.95)均显示明显保护作用。

临床怎么用

  • 原文结论为胃异型增生内镜切除后幽门螺杆菌治疗与胃癌及异时性胃肿瘤风险降低相关,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The study investigated the association between Helicobacter pylori treatment and the risk of gastric cancer after endoscopic resection of gastric dysplasia. METHODS: Patients who received endoscopic resection for gastric dysplasia between 2010 and 2020 from Korean nationwide insurance data were included. We verified the occurrence of new-onset gastric cancer and metachronous gastric neoplasm, which encompasses both cancer and dysplasia, >1 year after the index endoscopic resection. Newly diagnosed gastric cancer ≥3 years and ≥5 years was regarded as late-onset gastric cancer. A multivariable Cox regression model with H pylori treatment status as a time-dependent covariate was used to determine the risk of gastric cancer and metachronous gastric neoplasms. RESULTS: Gastric dysplasia in 69,722 patients was treated with endoscopy, and 49.5% were administered H pylori therapy. During the median 5.6 years of follow-up, gastric cancer developed in 2406 patients and metachronous gastric neoplasms developed in 3342 patients. Receiving H pylori therapy was closely related to lower gastric cancer risk (adjusted hazard ratio [aHR], 0.88; 95% confidence interval [CI], 0.80-0.96). H pylori treatment also significantly decreased metachronous gastric neoplasm development (aHR, 0.76; 95% CI, 0.70-0.82). Furthermore, H pylori therapy showed a prominent protective effect for late-onset gastric cancer development at ≥3 years (aHR, 0.84; 95% CI, 0.75-0.94) and ≥5 years (aHR, 0.80; 95% CI, 0.68-0.95). CONCLUSIONS: In this nationwide cohort, H pylori therapy after endoscopic resection of gastric dysplasia was associated with a reduced risk of gastric cancer and metachronous gastric neoplasm occurrence.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Yoo HW, Hong SJ, Kim SH, et al. Helicobacter pylori Treatment and Gastric Cancer Risk After Endoscopic Resection of Dysplasia: A Nationwide Cohort Study. Gastroenterology. 2023. PMID: 37863270. doi:10.1053/j.gastro.2023.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。